Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML. Roas M, Vick B, Kasper MA, Able M, et al. Blood 2023;141:1023-1035.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Roas M, Vick B, Kasper MA, Able M, et al. Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML. Blood 2023;141:1023-1035.
PMID: 35981498